$379 Million is the total value of COMMODORE CAPITAL LP's 29 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 41.4% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | Buy | IVERIC BIO INC | $44,662,000 | +304.9% | 2,750,137 | +57.3% | 11.78% | +206.4% |
| ACRS | Buy | ACLARIS THERAPEUTICS INC | $39,425,000 | +34.5% | 2,190,291 | +31.2% | 10.39% | +1.8% |
| CYTK | Buy | CYTOKINETICS INC | $28,470,000 | +104.3% | 796,578 | +13.1% | 7.51% | +54.6% |
| DRNA | New | DICERNA PHARMACEUTICALS INC | $26,052,000 | – | 1,292,251 | +100.0% | 6.87% | – |
| CCCC | C4 THERAPEUTICS INC | $21,495,000 | +18.1% | 481,094 | 0.0% | 5.67% | -10.7% | |
| KURA | Buy | KURA ONCOLOGY INC | $18,719,000 | +44.5% | 999,433 | +60.8% | 4.94% | +9.3% |
| CELC | Buy | CELCUITY INC | $16,568,000 | -20.7% | 920,464 | +5.7% | 4.37% | -40.0% |
| COGT | Buy | COGENT BIOSCIENCES INC | $16,084,000 | +45.0% | 1,912,511 | +39.8% | 4.24% | +9.8% |
| MRUS | New | MERUS N V | $15,799,000 | – | 718,136 | +100.0% | 4.16% | – |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $15,220,000 | -1.1% | 4,169,896 | +18.1% | 4.01% | -25.1% |
| STSA | Buy | SATSUMA PHARMACEUTICALS INC | $14,533,000 | -33.4% | 3,118,761 | +0.7% | 3.83% | -49.6% |
| VTGN | Buy | VISTAGEN THERAPEUTICS INC | $14,038,000 | +33.8% | 5,123,509 | +53.8% | 3.70% | +1.2% |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $13,401,000 | +23.9% | 248,207 | -23.3% | 3.53% | -6.2% |
| VRDN | Buy | VIRIDIAN THERAPEUTICS INC | $10,983,000 | +222.2% | 667,674 | +258.2% | 2.90% | +143.8% |
| New | TENAYA THERAPEUTICS INC | $10,613,000 | – | 513,930 | +100.0% | 2.80% | – | |
| IOVA | New | IOVANCE BIOTHERAPEUTICS INC | $8,948,000 | – | 362,869 | +100.0% | 2.36% | – |
| XENE | Buy | XENON PHARMACEUTICALS INC | $8,854,000 | +45.7% | 579,432 | +77.6% | 2.33% | +10.3% |
| PTGX | Buy | PROTAGONIST THERAPEUTICS INC | $8,826,000 | -6.6% | 498,079 | +136.5% | 2.33% | -29.3% |
| KRON | KRONOS BIO INC | $6,264,000 | -12.5% | 298,839 | 0.0% | 1.65% | -33.8% | |
| RVMD | New | REVOLUTION MEDICINES INC | $6,224,000 | – | 226,228 | +100.0% | 1.64% | – |
| GNCA | Buy | GENOCEA BIOSCIENCES INC | $5,913,000 | -13.7% | 3,079,756 | +5.1% | 1.56% | -34.7% |
| KALV | Buy | KALVISTA PHARMACEUTICALS INC | $5,454,000 | +0.4% | 312,553 | +37.9% | 1.44% | -24.0% |
| DYN | DYNE THERAPEUTICS INC | $4,955,000 | -22.8% | 305,125 | 0.0% | 1.31% | -41.6% | |
| MREO | Sell | MEREO BIOPHARMA GROUP PLCads | $4,775,000 | -26.9% | 1,972,958 | -4.2% | 1.26% | -44.7% |
| PMVP | PMV PHARMACEUTICALS INC | $3,725,000 | -12.8% | 125,000 | 0.0% | 0.98% | -34.0% | |
| IVA | INVENTIVA SAads | $3,719,000 | +3.9% | 262,658 | 0.0% | 0.98% | -21.4% | |
| BLSA | BCLS ACQUISITION CORP | $2,490,000 | -5.4% | 250,000 | 0.0% | 0.66% | -28.5% | |
| New | ASTRIA THERAPEUTICS INC | $2,115,000 | – | 239,270 | +100.0% | 0.56% | – | |
| SBTX | SILVERBACK THERAPEUTICS INC | $969,000 | -67.7% | 97,143 | 0.0% | 0.26% | -75.6% | |
| Exit | CATABASIS PHARMACEUTICALS IN | $0 | – | -1,617,000 | -100.0% | -1.19% | – | |
| MCRB | Exit | SERES THERAPEUTICS INC | $0 | – | -145,453 | -100.0% | -1.21% | – |
| MRSN | Exit | MERSANA THERAPEUTICS INC | $0 | – | -429,228 | -100.0% | -2.03% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -281,911 | -100.0% | -2.81% | – |
| MGNX | Exit | MACROGENICS INC | $0 | – | -393,850 | -100.0% | -3.69% | – |
| CNST | Exit | CONSTELLATION PHARMCETICLS I | $0 | – | -440,869 | -100.0% | -5.19% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.